Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Design Therapeutics ( (DSGN) ) has issued an announcement.
On March 31, 2026, Design Therapeutics appointed David Shapiro, M.D., to its board of directors as a Class III director, with a term running through the company’s 2027 annual shareholder meeting. He was also named to the board’s Nominating and Corporate Governance Committee, reinforcing the company’s governance structure and board oversight.
Under the company’s non-employee director compensation policy, Dr. Shapiro will receive annual cash retainers for his board and committee service and was granted stock options totaling 67,500 shares that vest over one- and three-year periods. The company also entered into its standard indemnification agreement with Dr. Shapiro, aligning his protections and incentives with those of other directors and signaling continuity in Design Therapeutics’ board compensation and risk-management practices.
The most recent analyst rating on (DSGN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
Moderate score driven by weak financial fundamentals (no revenue, ongoing losses and rising cash burn) despite a low-debt balance sheet. Technicals are a relative positive with price above major moving averages and improving momentum, while valuation remains pressured due to unprofitability and no dividend support.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Design Therapeutics is a biotechnology company focused on developing small-molecule therapies targeting serious genetic diseases. The company operates in the biopharmaceutical industry, concentrating on precision medicine approaches to address unmet medical needs in specialized patient populations.
Average Trading Volume: 264,622
Technical Sentiment Signal: Buy
Current Market Cap: $656.2M
See more insights into DSGN stock on TipRanks’ Stock Analysis page.